Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Agenus looks to new deals and an ex-US path
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Bristol cuts its BCMA losses
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Crunch time for Bristol’s TIGIT bet
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
FDA sends a warning about perioperative cancer studies
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
